HETEROARYL DERIVATIVES AS PARP INHIBITORS
Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein ring Ar, ring B, R1-R5, X, Y, p, q, r, and s are as defined in thespecification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt the...
Saved in:
Main Authors | , , , , , , , |
---|---|
Format | Patent |
Language | Chinese English |
Published |
17.04.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein ring Ar, ring B, R1-R5, X, Y, p, q, r, and s are as defined in thespecification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PARP enzyme of a subject.
本发明公开了式(I)化合物、其互变异构形式、其立体异构体或其药学上可接受的盐,其中,环Ar、环B、R-R、X、Y、p、q、r和s如说明书中所定义;还公开了包括上述化合物互变异构形式、其立体异构体或其药学上可接受的盐的药物组合物,还公开了治疗或预防疾病或失调,例如癌症的方法,可通过抑制试验对象中PARP酶来治疗或预防。 |
---|---|
Bibliography: | Application Number: CN201680047044 |